- Coordinator
- Medizinische Universitaet Wien, Austria
- Runs
- 1 January 2024 to 31 December 2028
- Status
- Running
- EU funding
- €3.5m
- Total cost
- €3.5m
- Partners
- 12 organisations in 8 countries
- Type
- European Innovation Council
- Grant agreement
- 101130093
What the project is doing
In the project's own words, from its summary on CORDIS.
The aim of I(eye)-Screen is to develop an artificial intelligence (AI)-based diagnostic decision support system for screening and monitoring of age-related macular degeneration (AMD) at an early stage before vision loss occurs. Late AMD is the leading cause of legal blindness >50 years with 110 mio individuals at risk. The multidisciplinary consortium brings together a network of clinical retina experts, computer scientists working at the cutting edge of AI development, an infrastructure of community-based opticians/optometrists and an SME experienced in digital platform performance to develop innovative and trustworthy AI tools for broad, real-time AMD screening and monitoring via a cloud-based infrastructure with unlimited access.
To achieve the ambitious goal of finding “the needle in the haystack” in early AMD, Optical Coherence Tomography (OCT), a high-resolution, effortless imaging modality is used providing a detailed characterization of the retina in extensive volumetric scans. Breakthrough AI approaches for medical imaging will be developed to enable data-efficient and robust learning from sparse longitudinal OCT data to systematically analyse dense data volumes and identify (sub)clinical markers of disease activity.
Clinical sites throughout Europe will collect a longitudinal cohort serving for calibrating and fine-tuning algorithms using the high-end OCT device available at eye clinics. Innovative AI technology will then be created to transfer the detection and monitoring tools to low-cost devices used in next door opticians’/optometrists’ offices. The timing of the project perfectly fits the recent regulatory approval of the first therapy to halt progression of the major atrophic type of AMD.
The resulting AI-based “shared care” strategy offers unrestricted accessibility to vision-maintaining care with greatest health equity and provides a role model for screening for systemic, cardiovascular and neurodegenerative disease reflecting retinal biomarkers.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Medizinische Universitaet Wien | Wien | Austria | Coordinator |
| Retinsight GmbH | Vienna | Austria | Participant |
| European Council of Optometry and Optics | Adligenswil | Switzerland | Associatedpartner |
| Universitat Zurich | Zurich | Switzerland | Associatedpartner |
| Vista Klinik Binningen | Binningen | Switzerland | Associatedpartner |
| Eurice European Research and Project Office GmbH | St Ingbert | Germany | Participant |
| Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer | Barcelona | Spain | Participant |
| Hospital Clinic De Barcelona | Barcelona | Spain | Third party |
| Centre Hospitalier Reg Universitaire Dijon | Dijon | France | Participant |
| Research and Innovation Services Doo Za Usluge | Zagreb | Croatia | Third party |
| Univerzitetni Klinicni Center Ljubljana | Ljubljana | Slovenia | Participant |
| The Queen's University of Belfast | Belfast | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI